The University of Missouri has marked a pivotal moment in cancer research with the launch of its first in-person clinical trial for an innovative nuclear medicine device known as Eye90 microspheres. Conducted at the Ellis Fischel Cancer Center, this trial represents a seamless integration of cutting-edge isotope production, preclinical testing, and human application all on one campus. On February 9, 2026, the first patient received treatment, targeting unresectable liver tumors—a development that underscores Mizzou's leadership in translational research within higher education.
This breakthrough stems from the university's unique infrastructure, particularly the Missouri University Research Reactor (MURR), the nation's most powerful university-operated research reactor. By producing yttrium-90 (Y-90)—a critical radioisotope—MURR enables therapies that deliver targeted radiation directly to tumors, sparing healthy tissue. The trial's initiation highlights how universities like Mizzou are bridging the gap between laboratory innovation and patient care, potentially transforming outcomes for hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
The Critical Role of MURR in Nuclear Medicine Advancement
The MU Research Reactor, operational since 1966 at 10 megawatts, has a storied history in nuclear medicine. It pioneered the development of Y-90 glass microspheres in the 1980s through collaborations between Mizzou researchers and Missouri University of Science and Technology. This led to TheraSphere, the first FDA-approved Y-90 therapy for liver cancer in 2021, with MURR remaining the sole U.S. producer.
MURR's capabilities extend beyond production; it irradiates and processes isotopes for clinical use, supporting over 500,000 cancer patients annually worldwide. Its reliability—operating nearly continuously—ensures a domestic supply chain free from foreign dependencies. For Eye90, MURR provides the Y-90 activation, making Mizzou a one-stop hub for radioisotope therapy development. This vertical integration accelerates innovation, a model other universities aspire to replicate in biomedical engineering and radiology programs.
University President Mun Choi emphasized this synergy: “This clinical trial shows the power of our campus research... allowing faculty to partner with industry to develop and test ground-breaking treatments faster, all from one campus.” Such infrastructure positions Mizzou as a leader in higher education's push toward precision medicine.
Understanding Eye90 Microspheres: A Game-Changer in Targeted Therapy
Eye90 microspheres are tiny radiopaque glass beads, approximately 20-30 micrometers in diameter, infused with Y-90. Unlike traditional non-visible microspheres, Eye90's radiopacity allows real-time fluoroscopic imaging during transarterial radioembolization (TARE). Interventional radiologists can guide delivery precisely via catheter to the hepatic artery feeding the tumor, confirming placement before radiation emission.
Y-90 decays via beta emission, delivering high-energy electrons with a half-life of 2.67 days and tissue penetration of 2.5-11 mm—ideal for liver tumors up to 5 cm. The process involves:
- Diagnostic angiography to map tumor blood supply.
- Simulation with technetium-99m to assess lung shunting.
- Therapeutic infusion of Eye90, monitored live.
- Post-treatment SPECT/CT imaging for dosimetry.
This step-by-step visualization reduces off-target effects, potentially improving efficacy over standard Y-90 therapies like TheraSphere or SIR-Spheres.
Details of the Landmark Clinical Trial
The trial, registered as NCT05953337 and sponsored by ABK Biomedical, is a prospective, multi-center, open-label study evaluating Eye90's safety and effectiveness in unresectable HCC patients. Mizzou's site focuses on single-dose administration followed by one-year monitoring of tumor response, progression-free survival, and quality of life via imaging and biomarkers.
First patient enrollment occurred February 9, 2026, at Ellis Fischel Cancer Center. Eligibility includes Barcelona Clinic Liver Cancer (BCLC) stage A-D patients with liver-dominant disease. Primary endpoints: objective response rate per RECIST 1.1 criteria; secondary: overall survival, adverse events per CTCAE v5.0. ABK's ROUTE90 pivotal study recently completed 120-patient enrollment, building momentum toward FDA approval—Eye90 holds Breakthrough Device Designation since 2023.Learn more about the trial on ClinicalTrials.gov.
Ryan Davis, associate professor of clinical radiology and on-site coordinator, noted: “This is the first radiopharmaceutical clinical trial for Ellis Fischel... providing early availability of therapies and continuing our leadership in translational research.”
Key Faculty Driving the Innovation
Mizzou's interdisciplinary team exemplifies higher education's collaborative ethos. Jeffrey Bryan, professor of oncology in the College of Veterinary Medicine and associate director of comparative oncology at Ellis Fischel, led preclinical dog studies demonstrating Eye90's safety and efficacy. These veterinary trials at MU Veterinary Health Center's PET Imaging Center paved the way for human application.
Davis oversees human dosing, leveraging Mizzou's radiology expertise. Matt Sanford, MURR executive director, highlights production: “By leveraging our expertise... we are helping bring innovative cancer treatments from laboratory to clinic.” This faculty-industry synergy—fueled by NextGen Precision Health—positions Mizzou faculty for grants, publications, and patents, enhancing academic careers in nuclear oncology.
Liver Cancer Burden and Treatment Landscape
Hepatocellular carcinoma accounts for 75-85% of U.S. primary liver cancers, with ~42,000 new cases and 30,000 deaths annually (American Cancer Society estimates). Risk factors include cirrhosis (70% cases), hepatitis B/C, NAFLD, and alcohol. Unresectable HCC (80% at diagnosis) has median survival of 6-16 months without treatment.
Standard options: sorafenib (OS ~10 months), TACE (transarterial chemoembolization, OS 15-20 months). Y-90 TARE offers OS 12-30 months, better tolerability, and bridging to transplant (15-26% success). Meta-analyses show Y-90 prolongs time-to-progression vs TACE (HR 0.48-1.67). Eye90's visibility could further optimize dosimetry, reducing radiation-induced liver disease (5-10% risk).U.S. liver cancer statistics from American Cancer Society.
Mizzou's Legacy in Nuclear Medicine Research
Since inventing Y-90 microspheres, MURR has produced isotopes treating millions, including Mo-99 for cardiac imaging (half global supply post-2009 shortages). It supports 500+ clinical trials yearly, from Lu-177 PSMA for prostate cancer to Ac-225 for targeted alpha therapy.
Mizzou's veterinary-human translation model—using pet dogs for oncology trials—accelerates safety data. This 'One Health' approach trains students in radiology, oncology, and reactor engineering, fostering interdisciplinary PhDs and postdocs.
Future Horizons: NextGen MURR and Beyond
The $1B NextGen MURR (20 MW reactor) will quadruple isotope output, securing U.S. supply for emerging therapies like F-18 for PET/CT. Funded by $200M+ (state $50M, federal), it launches 2030, creating 500 jobs and boosting Mizzou's research GDP impact ($1.2B annually).
U.S. nuclear medicine market: $5.1B (2023), projected $9.56B by 2030 (14.7% CAGR), driven by theranostics.Market projections from MarketsandMarkets. Mizzou aims to lead, training next-gen experts via clinical-research-jobs.
Implications for Higher Education and Research Careers
This trial exemplifies how research universities drive healthcare innovation, attracting federal grants (NIH, DOE) and industry partnerships. Faculty like Bryan and Davis mentor students in radiopharmacy, imaging analysis—skills in demand for /research-jobs and /clinical-research-jobs.
Challenges: Regulatory hurdles, isotope shortages. Solutions: MURR's expansion, interdisciplinary programs. For aspiring academics, Mizzou offers /higher-ed-jobs/faculty in nuclear medicine, blending teaching, research, and impact.
In summary, Mizzou's Eye90 trial heralds a new era in university-led nuclear medicine, promising better HCC outcomes and reinforcing higher education's role in lifesaving tech. As NextGen MURR rises, expect more breakthroughs from Columbia, Missouri.
